41st Pharmacovigilance USA 2026

41st Pharmacovigilance USA 2026

27 & 28 May, 2026, Wyndham Boston Beacon Hill, Boston, USA

Virtue Insight is proud to announce its 41st Pharmacovigilance 2026. We have been delivering the conference through close collaboration with the industry leaders for more than a decade. For the 2026 edition, the agenda includes a host of new and exciting features. Take a chance and make it count by attending this conference to network with your peers, exchange expertise and experiences, and arm yourself with the latest information to take your department to the next level.

Please contact me for Sponsor / Exhibit / Booth / Delegate at E-mail - [email protected] or Call - +44 20 3509 3779

SPONSORSHIP:

Platinum Sponsor - Arisglobal

Bronze Sponsor - 4C Pharma Solutions

We have more sponsorship opportunities available for the event, which gives you an opportunity to exhibit/booth/speak and create brand awareness. Please email to [email protected] for more details.

DELEGATE REGISTRATION:

Super Early Bird Price - Valid Till 27th Mar 2026

01 Delegate - $ 899

3 Delegates for the price of 2 - $ 1798

Early Bird Discount Price (Valid till 28th Mar 2026 - 30th Apr 2026)

01 Delegate - $1199

3 Delegates for the price of 2 - $2398

Standard Price (From 1st May 2026)

01 Delegate - $1499

3 Delegates for the price of 2 - $2998

KEY SPEAKERS:

· MARIETTE BOERSTOEL-STREEFLAND, SVP, Worldwide Patient Safety Officer, Bristol-Myers Squibb

· PHILISHA MACK, Sr. Director of Drug Safety, Medical Affairs, Azurity Pharmaceuticals

· E. ALTON SARTOR, Medical Director, Patient Safety Physician Digital & Devices, AstraZeneca

· NICOLE SCHUMACHER-CROW, Continuous Improvement Center of Excellence Head - Senior Director, Pfizer

· HARSHA SHETTY, Senior Director, Global Safety Lead & Patient Engagement, CSL Behring

· KARTHIK MUTHUSAMY, Executive Director, Head of US Patient Safety, Novo Nordisk

· DEANNA MONTES DE OCA, Sr. Director, Global Head of PV Operations Case Management, Moderna

· WENDY ERLER, SVP Patient Affairs, Sarepta Therapeutics

· EDDIE DARTON, VP - Head Global PV & Risk Management, Sarepta Therapeutics

· SUSAN WNOROWSKI, Sr. Director, US Medical Information and Patient Safety, Ipsen

· SHALINI PATEL, Sr. Director PV Operations - Pharmacovigilance Center of Excellence, Moderna

· MICHAEL GLASER, Technology Innovation Director, GSK

· MICHELE COIRO, Director, US REMS Strategy & Submissions, Bristol-Myers Squibb

· VASUDEV BHUPATHI, Director – Pharmacovigilance, Moderna

· MANJIRI NIRGUDKAR, Director; Global Process Lead - Global Risk Management, Bristol-Myers Squibb

· ALLISON CONCANNON, Director, Global Patient Safety, Americas Lead, Ipsen

· JIAN-YU E, Director of Pharmacoepidemiology, Patient Safety & PV (PSPV), Sanofi

· JULIE BARBERIO, Director, Pharmacoepidemiology, Sanofi

· VIKALP KHARE, Director, Head of US GPV Safety Data Management, Otsuka Pharmaceutical

· ASHRAF YOUSSEF, Global Senior Medical Director, Post Marketed Products, Global Safety Lead, Takeda Pharmaceuticals

· SHEFALI JOBANPUTRA, Associate Director, CPASS Compliance Process, and Training Lead, Takeda

· TEODORA DOHERTY, Global Medical Safety (GMS), Medical Safety Officer, Janssen R&D

· JILLIAN HORVATH, Associate Director, Global RMP (Pharmacovigilance), Jazz Pharmaceuticals

· BEN LOCWIN, VP Board of Directors, SOPPhC (VP, Reliant Life Sciences)

· MILIND SARDESAI, Executive Director, Safety Surveillance Global Patient Safety, Dicerna Pharmceuticals

· SUMIT MUNJAL, Global Head of Medical Safety, Otsuka Pharmaceutical

· KAL ELHOREGY, Director, Risk Evaluation and Mitigation Strategy (REMS) Programs, Amneal Pharmaceuticals

· WILLIAM A. BLUMENTALS, Head of Pharmacoepidemiology Specialty Care, Sanofi

· PRIYANKA CHHIKARA, Head of Risk Management, Aggregate Reports & Data Science, CSL Behring

· MALLIKA SINGH, Associate Director, Pharmacovigilance, Genetix Biotherapeutics

· KAPIL BHUTADA, Head of PV Safety Operation & Compliance, Asklepios BioPharmaceutical

· ANUJ PARIKH, Associate Medical Director, Medical Safety, Jazz Pharmaceuticals

· NAMITA JOSHI, Regional PV Head, North America, Opella

· SANDY DIAZ, Owner & Principal Consultant, Pharmacovigilance Solutions

· REEM YASIN, Quality Assurance & PV Manager, Hawkary Pharmaceuticals, Kawkab group (Iraq)

· HEATHER LEIGH FLANNERY, CEO & Co-Founder, AI MINDSystems Foundation

· VINEET SINGH, Head of PV Data Science and Analytics, CSL Behring

· NINA TEO, Senior Manager, Global Patient Safety & Risk Management, Alnylam Pharmaceuticals

Plus More Joining Soon...

FOCUS AREAS:

CHALLENGES / OPPORTUNITIES

MARKET TRENDS- CRITIQUES & WAYS FORWARD

PATIENT SAFETY/ PATIENT CENTRICITY

OUTSOURCING

RWE / RWD

RMP/ REMS

AUDITS & INSPECTION

IMPACT OF TECHNOLOGY AI, ML, DA

QUALITY, SAFETY & SIGNAL DETECTION

AUTOMATION IN PV

REGULATORY

WHO SHOULD ATTEND:

CEO’s, CTO’s, CIO’s, Presidents, VPs, Directors, Heads, Managers, Scientific Advisors, Consultants of:

Pharmacovigilance, Pharmacoepidemiology, Pharmacogenomics, Drug/Product Safety, Drug Development, Information and Clinical Data Management, Clinical Pharmacology, Clinical Safety, Periodical safety update Reports, Risk Management, Research & Development, Quality Assurance, Patient Safety, Signal Detection, Safety Surveillance, Outcomes Research, Data Analysis, Epidemiology, Medical Affairs, Regulatory Affairs and Compliance, Information technology, Sales and Marketing.

Get more from the event, with a broader scope bringing the whole communications value chain together. Enjoy and make the best out of our dedicated networking time, and meet the leading international vendors showcasing the products of tomorrow in the co-located exhibition. Expand your knowledge of the latest business models and strategies at the high-levelconference.

Know what’s Happening Next — before everyone else does.

Get App

Host or Publisher Virtue Insight